Proibidos cosméticos clandestinos
http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/4450653
http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/4450653
The Food and Drug Administration (FDA) is announcing the following public symposium entitled ‘‘2018 Center for Biologics Evaluation and Research Science Symposium.’’ The purpose of the public symposium is to discuss scientific topics related to the regulation of biologics and highlight science conducted at the Center for Biologics Evaluation and Research (CBER) by showcasing how scientific research informs regulatory decision making and to provide a forum for developing collaborations within FDA and with external organizations. The symposium will include presentations by experts from academic institutions, government agencies, and research institutions.
DATES
The public symposium will be held on June 25 and 26, 2018, from 9 a.m. to 3 p.m.
TOPICS FOR DISCUSSION
The public symposium will include presentations on the following topics:
(1) Emerging and re-emerging diseases;
(2) diverse types of data in regulatory decision making;
(3) immune response to vaccination;
(4) immunotherapy;
(5) new technologies for research and treatments; (6) the role of the microbiome in human disease; and
(7) regenerative medicine.
PARTICIPATON
Participating in the Public Symposium could be in person or by webast.
Registration is free and based on space availability, with priority given to early registrants. Persons interested in attending this public symposium (either in person or by webcast) (see Streaming Webcast of the Public Symposium) must register online by June 18, 2018, midnight Eastern Time. Early registration is recommended because seating is limited. There will be no onsite registration; therefore, FDA may limit the number of participants from each organization. Registrants will receive confirmation when they have been accepted.
For more information go to https://www.gpo.gov/fdsys/pkg/FR-2018-03-22/pdf/2018-05805.pdf
http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/4450055
FDA issued a guidance for industry entitled ‘‘Bioanalytical Method Validation.’’ This guidance incorporates public comments to the revised draft published in 2013 as well as the latest scientific feedback concerning bioanalytical method validation and provides the most up-to-date information needed by drug developers to ensure the bioanalytical quality of their data.
To access the guidance go to https://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf
http://www.who.int/world-health-assembly/seventy-first
The Seventy-first World Health Assembly: Interview with Dr. James Fitzgerald, Director of Health Systems and Services PAHO/WHO about Universal health coverage: what it means and how we can achieve it: http://www.who.int/world-health-assembly/seventy-first/social-good
The World Health Assembly The World Health Assembly (WHA) is the decision-making body of WHO. It is attended by delegations from all WHO Member States and focuses on a specific health agenda prepared by the Executive Board.
The main functions of the World Health Assembly are to determine the policies of the Organization, supervise financial policies, and review and approve the proposed programme budget.
This year’s Health Assembly takes place on 21–26 May 2018 in Geneva, Switzerland.
Live at http://www.who.int/world-health-assembly/seventy-first
Following the WHA at http://www.who.int/world-health-assembly/seventy-first/social-good
World Health +SocialGood : Show schedule
Bringing health to all
Keeping healthy in today’s world
Keeping the world safe, serving the vulnerable
For more information about the Seventy-first WHA, go to http://www.who.int/world-health-assembly/seventy-first
http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/4447170